GERATHERM MEDICAL AG Geratherm Medical AG | Quarterly Statement Q1/2021 | 2 |
GERATHERM
Facts and figures
Sales revenues
of which export share
Export ratio
Gross result for period under review (EBITDA)
EBITDA margin
Amortisation and depreciation
Operating result (EBIT)
EBIT margin
Financial results
Profit (loss) on ordinary business activities
Net earnings of the parent company's shareholders in given period
Long-term assets
Short-term assets
Balance sheet total
Equity capital
Return on equity
Equity ratio
Cash, cash equivalents and securities
Net result per share for given period according to IFRS (EPS)**
Net result per share for given period as per DVFA** (German
Association for Financial Analyses and Asset Management)
Number of employees at end of period
Total shares issued
**based on total shares issued
AT A GLANCE
January- | January- | Change | ||
March | March | % | ||
2021 | 2020 | |||
6,660 kEUR | 6,253 kEUR | 6.5% | ||
5,210 kEUR | 5,341 kEUR | -2.5% | ||
78 % | 85 % | -8.2% | ||
1,051 kEUR | 671 kEUR | 56.7% | ||
15.8 % | 10.7 % | 47.7% | ||
-375 kEUR | -299 kEUR | 25.4% | ||
676 kEUR | 372 kEUR | 81.8% | ||
10.2 % | 5.9 % | 72.9% | ||
-31 kEUR | -24 kEUR | 27.0% | ||
645 kEUR | 348 kEUR | 85.6% | ||
422 kEUR | 287 kEUR | 46.9% | ||
14,794 kEUR | 13,340 kEUR | 10.9% | ||
22,143 kEUR | 20,276 kEUR | 9.2% | ||
36,937 kEUR | 33,616 kEUR | 9.9% | ||
20,911 kEUR | 18,665 kEUR | 12.0% | ||
8.1 % | 6.2 % | 31.2% | ||
56.6 % | 55.5 % | 2.0% | ||
9,361 kEUR | 8,159 kEUR | 14.7% | ||
EUR 0.09 | EUR 0.06 | 50.0% | ||
EUR 0.09 | EUR 0.06 | 50.0% | ||
242 | 211 | 14.7% | ||
4,949,999 | 4,949,999 | 0.0% | ||
4,949,999 | 4,949,999 | 0.0% | ||
Geratherm Medical AG | Quarterly Statement Q1/2021 | 3 |
Business Performance from 1 January to 31 March 2021
- Sales revenues EUR 6.7 million +6.5 %
- Gross result for first quarter (EBITDA) EUR 1.051 million +56.7 %
- Operating result (EBIT) 676 kEUR +81.8 %
- EBIT margin 10.2 % (2020: 5.9 %)
- Results from ordinary activities 645 kEUR (2020: 348 kEUR).
- Earnings per share 9 EUR cents (2020: 6 EUR cents)
Dear Shareholders and Parties Interested in Geratherm Medical,
We managed the renewed lockdown in the first quarter of 2021 without any major disruptions. On the whole, we were able to increase sales by +6.5 % in the first three months, showing a considerably higher result. The positive earnings trend was supported primarily by the better performance posted by the subsidiaries Respiratory, apoplex and LMT. The earnings posted at the location in Thuringia slid in the first three months. This could be attributed here to the increased expenses for medical device approvals in accordance with MDR.
The gross result of the overall performance was EUR 4.577 million (2020: EUR 4.052
million). The gross margin on sales was 68.7 % (2020: 64.8 %). The gross earnings (EBITDA) increased by +56.7 % to EUR 1.051 million in the first three months of the business year. During the first quarter, the operating result EBIT was 676 kEUR (2020: 372 kEUR).
The result from ordinary business activities was 645 kEUR (2020: 348 kEUR). The shareholders' result after taxes for the first quarter amounted to 422 kEUR (2020: 287 kEUR) or EUR 0.09 per share (2020: EUR 0.06).
Geratherm Medical AG | Quarterly Statement Q1/2021 | 4 |
Facts and figures | I/21 | IV/20 | III/20 | II/20 | I/20 | |
(in kEUR) | ||||||
Sales | 6,660 | 7,707 | 5,912 | 7,594 | 6,253 | |
EBITDA margin | 15.8 % | 16.8% | 16.9% | 18.2% | 10.7% | |
EBIT | 676 | 899 | 686 | 1,082 | 372 | |
EPS (EUR) | 0.09 | 0.10 | 0.10 | 0.15 | 0.06 | |
Cash flow | 1,072 | 1,267 | 1,160 | 1,531 | 1,043 | |
Sales development
The sales development by regions was not uniform in the first quarter of 2021 and was partly influenced by different lockdown intervals in the individual regions. In the first three months, we managed to increase Group sales by +6.5 % over the previous year.
There was a slight decrease in sales of -6.2 % on the European market. On the German market, we were able to register a very favourable increase in sales. Sales in Germany in the first three months were +59.0 % higher than in the same period of the previous year. After the coronavirus blockades were lifted for the most part in the Middle East, we were able to report a very favourable +263.9 % growth in sales. On the US market, sales posted in the first quarter fell slightly by -10.0 % compared to the same period last year. We recorded a greater drop in sales at a low level in South America, declining here by -41.6 %. After a very strong first quarter last year, we posted a -48.6 % decline in sales in the Other countries region.
Sales by regions 1/1 to 31/3/2021
as of | as of | |||||||||
4% | 31/3/2021 | 31/3/2020 | ||||||||
11% | kEUR | kEUR | ||||||||
2% | Europe | 3,723 | 3,967 | -6.2% | ||||||
5% | ||||||||||
Germany | 1,450 | 912 | +59.0% | |||||||
USA | 360 | 400 | -10.1% | |||||||
56% | South America | 167 | 286 | -41.6% | ||||||
22% | Middle East | 706 | 194 | +263.9% | ||||||
Other countries | 254 | 494 | -48.6% | |||||||
Länder |
Geratherm Medical AG | Quarterly Statement Q1/2021 | 5 |
Geratherm Medical's products are primarily marketed internationally. In the first quarter, 78.2 % (2020: 85.4 %) of Geratherm products were exported.
Sales by segments 1/1 to 31/3/2021
as of | as of | |||||||||||||
31/3/2021 | 31/3/2020 | |||||||||||||
8% | kEUR | kEUR | ||||||||||||
7% | ||||||||||||||
Healthcare Diagnostic | 4,116 | 4,077 | +1.0% | |||||||||||
23% | Respiratory | 1,509 | 1,256 | +20.1% | ||||||||||
62% | Med. warming systems | 453 | 356 | +27.2% | ||||||||||
Cardio/Stroke | 582 | 564 | +3.2% | |||||||||||
In the Healthcare Diagnosticsegment, where we primarily market clinical thermometers, blood pressure monitors and women's health products to pharmacies and drugstores world-wide, we showed a slight increase of +1.0 % in sales. Shifts occurred between the individual product groups during the first quarter. Sales of blood pressure monitors were considerably stronger. With regard to clinical thermometers, we showed temporary declines in individual product groups compared to the same period last year. In the Women's Health product segment, we did register strong growth. All in all, you have the impression that products, which are not associated with the coronavirus, have significant ground to make up. The Healthcare Diagnostic segment accounted for 61.8 % of the total sales generated by the Geratherm Group.
In the Respiratorysegment, where we offer sensors and products for monitoring pulmonary functions, we currently have a high demand for products that are needed for long-term COVID treatment. Sales posted by medical devices for measuring pulmonary function increased by +20.1 % in the first three months. The growth momentum is likely to continue in the new few quarters.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Geratherm Medical AG published this content on 20 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 May 2021 07:47:06 UTC.
